ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLNN Clene Inc

0.37
-0.0156 (-4.05%)
May 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 319,221
Bid Price 0.37
Ask Price 0.3823
News -
Day High 0.392

Low
0.25

52 Week Range

High
1.09

Day Low 0.3709
Company Name Stock Ticker Symbol Market Type
Clene Inc CLNN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0156 -4.05% 0.37 19:33:42
Open Price Low Price High Price Close Price Prev Close
0.392 0.3709 0.392 0.37 0.3856
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
529 319,221 $ 0.3824473 $ 122,085 - 0.25 - 1.09
Last Trade Time Type Quantity Stock Price Currency
19:34:58 formt 2,000 $ 0.37 USD

Clene Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
48.8M 128.43M - 654k -49.5M -0.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Clene News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CLNN Message Board. Create One! See More Posts on CLNN Message Board See More Message Board Posts

Historical CLNN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.40630.4270.3610.3864944356,772-0.0363-8.93%
1 Month0.32950.43970.31310.3936062512,7590.040512.29%
3 Months0.450.520.3040.3770525891,511-0.08-17.78%
6 Months0.4560.600.250.3797969932,698-0.086-18.86%
1 Year0.90281.090.250.4905056701,012-0.5328-59.02%
3 Years7.2917.820.252.49550,053-6.92-94.92%
5 Years9.5517.820.252.91510,783-9.18-96.13%

Clene Description

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Your Recent History

Delayed Upgrade Clock